Deterding K, Manns M P, Wedemeyer H
Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland.
Internist (Berl). 2018 Apr;59(4):401-409. doi: 10.1007/s00108-018-0390-9.
Treatment of chronic hepatitis C (HCV) has changed dramatically since the approval of the direct-acting antivirals (DAA). Depending on the HCV genotype and the stage of liver disease, sustained HCV clearance can be achieved in more than 95% of patients with a treatment duration of 8-12 weeks in most of the cases. The selection and combination of the drugs depends on previous antivirals therapies, the stage of liver fibrosis, HCV genotype and subtype, viral load at baseline, and renal function. Nowadays, potent antiviral therapy with minimal side effects can be offered to almost every patient. In the real-world setting, a high quality of HCV therapy considering economic aspects has been documented in the German Hepatitis C Registry. A reduction of clinical complications of chronic liver disease by clearance of HCV has already been documented.
自从直接作用抗病毒药物（DAA）获批以来，慢性丙型肝炎（HCV）的治疗发生了巨大变化。根据HCV基因型和肝病阶段，在大多数情况下，8 - 12周的治疗疗程可使超过95%的患者实现HCV持续清除。药物的选择和联合取决于既往抗病毒治疗、肝纤维化阶段、HCV基因型和亚型、基线病毒载量以及肾功能。如今，几乎每位患者都能接受副作用极小的强效抗病毒治疗。在现实环境中，德国丙型肝炎登记处已记录了考虑经济因素的高质量HCV治疗情况。HCV清除已被证明可减少慢性肝病的临床并发症。
